Core Viewpoint - Santhera Pharmaceuticals reports a strong commercial momentum with AGAMREE, achieving 98% revenue growth in 2025, driven by increased adoption in European markets and strategic partnerships, positioning the company favorably in the rare disease sector [1][4]. Financial Performance - Total revenue for 2025 reached CHF 77.4 million, up from CHF 39.1 million in 2024, significantly exceeding the initial guidance of CHF 65–70 million [4]. - Product sales increased by 72% to CHF 25.8 million, reflecting strong AGAMREE adoption in Germany, Austria, and early sales in the UK [4]. - Royalties and milestones rose by 37% to CHF 23.1 million, driven by strong performance from licensing partner Catalyst Pharmaceuticals, including a USD 12.5 million sales milestone payment [4][7]. - Revenue from product and service supply to partners was CHF 28.5 million, up from CHF 7.2 million in 2024 [4]. Operational Highlights - AGAMREE's launch in the UK is progressing well, with uptake trends mirroring those in Germany [4]. - The company anticipates reaching cash flow breakeven in Q3 2026, with no additional funding required [4]. - Santhera entered into a strategic licensing agreement with Nxera Pharma for Japan and other APAC markets, valued at up to USD 205 million, including a USD 40 million upfront payment [4][5]. Market Expansion - Santhera has broadened its global access through new distribution partnerships in regions including GCC countries, India, Türkiye, and Russia [7]. - The company is targeting further launches across Europe in 2026, including Italy and Nordic markets, contingent on local regulatory processes [4]. Research and Development - Positive long-term data from the GUARDIAN study showed AGAMREE's efficacy comparable to standard corticosteroids, with an improved safety profile [7]. - The company plans to promote these findings to physicians, which is expected to enhance sales in 2026 [7]. Leadership and Governance - Santhera has strengthened its leadership team with new appointments, including a Chief Financial Officer and a Chief Commercial Officer, to drive future growth [7].

Core Insights - Catalyst Pharmaceuticals is showcasing real-world findings in Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference, emphasizing their commitment to advancing research and patient care [1][2] Poster Presentations - The company will present multiple posters focusing on the real-world analysis of vamorolone, a novel corticosteroid, in DMD patients, including studies on cardiac medication use and glucocorticoid treatment duration [3][4] - Specific poster titles include "Real-world analysis of concomitant cardiac medication use with the novel corticosteroid vamorolone in patients with Duchenne muscular dystrophy" and "Association Between Glucocorticoid Treatment Duration and Health Care Resource Utilization in Duchenne Muscular Dystrophy" [3][4] Symposium - Catalyst Pharmaceuticals is sponsoring an MDA Industry Forum in conjunction with Santhera Pharmaceuticals, which will feature insights from clinical leaders on advancing understanding of DMD [5][6] Company Overview - Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a strong commitment to patient care and accessibility [6] - The company has been recognized by Forbes as one of America's Most Successful Companies for three consecutive years (2023-2025) and listed on the 2025 Deloitte Technology Fast 500™ as one of North America's Fastest-Growing Companies [6]

Group 1 - Catalyst Pharmaceutical (CPRX) reported revenue of $152.61 million for the quarter ended December 2025, reflecting a 7.6% increase year-over-year and a 9% surprise over the Zacks Consensus Estimate of $140.02 million [1] - The earnings per share (EPS) for the quarter was $0.68, down from $0.70 in the same quarter last year, with a significant EPS surprise of +60.95% compared to the consensus estimate of $0.42 [1] - The stock has returned +2.7% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change, and currently holds a Zacks Rank 3 (Hold) [3] Group 2 - Product revenue net for the quarter was $152.5 million, exceeding the average estimate of $140.01 million from four analysts, marking a year-over-year change of +7.5% [4] - FIRDAPSE generated $97.62 million in revenue, surpassing the estimated $96.43 million, representing an 18.3% increase year-over-year [4] - AGAMREE revenue reached $35.3 million, exceeding the average estimate of $31.3 million, with a year-over-year change of +67.5% [4] - FYCOMPA reported revenue of $19.58 million, compared to the average estimate of $12.28 million, indicating a year-over-year decline of -48.8% [4] - License and other revenues were $0.11 million, significantly higher than the estimated $0.03 million, reflecting a remarkable +909.1% change year-over-year [4]

Financial Data and Key Metrics Changes - Total revenues for 2025 grew by 19.8% year-over-year to $589 million, exceeding previous guidance of $565 million to $585 million [3][21] - Full year net product revenue reached $588.8 million, a 20.3% increase over 2024 [4][23] - Net income before income taxes for 2025 was $283.5 million, a 31.1% increase compared to $216.3 million for 2024 [23] - GAAP net income for 2025 was $214.3 million or $1.68 per diluted share, up 30.8% from $163.9 million or $1.31 per diluted share in 2024 [24][23] Business Line Data and Key Metrics Changes - Firdapse revenue for 2025 was $358.4 million, an increase of 17% year-over-year [6][13] - AGAMREE achieved 2025 revenues of $117.1 million, reflecting 154.3% year-over-year growth [8][17] - Fycompa delivered net revenue of $113.3 million in 2025, exceeding expectations despite generic competition [10][19] Market Data and Key Metrics Changes - The addressable market for LEMS is estimated to be in excess of $1 billion, with significant growth opportunities identified in both idiopathic and cancer-associated LEMS [7][16] - The average age of new AGAMREE enrollees dropped by one year, indicating a shift towards younger patients [58] Company Strategy and Development Direction - The company aims to maximize the potential of its differentiated products through targeted patient identification and market penetration strategies [11][32] - Business development efforts are focused on identifying rare disease products with peak sales potential of up to $500 million [12][11] - The company plans to continue lifecycle management activities and explore additional indications for AGAMREE [90][91] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, with revenue guidance set between $615 million and $645 million [4][23] - The company remains focused on executing dual market expansion strategies for Firdapse and deepening market penetration for AGAMREE [32][20] Other Important Information - The company ended 2025 with cash and cash equivalents of $709.2 million, up from $517.6 million at the end of 2024 [30] - Research and development expenses were $12.7 million in 2025, with expectations for increased spending in 2026 [29][28] Q&A Session Summary Question: Drivers of growth for 2026 guidance for Firdapse and AGAMREE - Management highlighted the significant pool of identified patients and increased RGCC testing as key drivers for growth [36][39] Question: Impact of Firdapse growth guidance exceeding historical rates - Management noted confidence from the increased pool of patients and improved efficiency in patient conversion [43][44] Question: AGAMREE's commercial performance and reimbursement landscape - Management confirmed strong reimbursement rates above 85% and noted a decrease in the median age of new enrollees [55][57] Question: SUMMIT study's impact on AGAMREE forecast - Management indicated that while the SUMMIT study is important, no significant impact is currently built into the 2026 guidance [66][70] Question: Business development activities in light of market conditions - Management reported no change in the quality of inbound opportunities and remains focused on strategic evaluations [75][76]

Financial Data and Key Metrics Changes - Total revenues for 2025 reached $589 million, a 19.8% increase from $491.7 million in 2024, exceeding previous guidance [3][21] - Net product revenue for 2025 was $588.8 million, reflecting a 20.3% increase over 2024 [4][23] - GAAP net income for 2025 was $214.3 million, or $1.68 per diluted share, a 30.8% increase compared to $163.9 million in 2024 [24][23] - Non-GAAP net income for 2025 was $346.2 million, or $2.72 per diluted share, compared to $276.3 million, or $2.21 per diluted share in 2024 [24][25] Business Line Data and Key Metrics Changes - Firdapse generated $358.4 million in revenue for 2025, a 17% increase year-over-year [6][13] - AGAMREE achieved $117.1 million in revenue for 2025, representing a remarkable 154.3% year-over-year growth [8][17] - Fycompa generated $113.3 million in revenue for 2025, with expectations of $40 million to $45 million for 2026 due to generic competition [10][23] Market Data and Key Metrics Changes - The addressable market for LEMS is estimated to exceed $1 billion, with significant growth opportunities identified in both idiopathic and cancer-associated LEMS [7][16] - The addressable market for AGAMREE is also projected to be over $1 billion, with ongoing studies expected to enhance its market position [8][9] Company Strategy and Development Direction - The company aims to maximize the value of its commercial portfolio through personalized support for patients with rare diseases [3][32] - Strategic focus includes dual market expansion for Firdapse and deepening market penetration for AGAMREE [32] - The company is pursuing business development opportunities for differentiated rare disease products, with a focus on assets with peak sales potential of up to $500 million [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, with 2026 revenue guidance set between $615 million and $645 million [4][22] - The company highlighted the importance of patient identification and market penetration as key drivers for future growth [6][39] - Management acknowledged the challenges posed by generic competition but remains optimistic about the long-term potential of its product portfolio [10][23] Other Important Information - The company ended 2025 with cash and cash equivalents of $709.2 million, up from $517.6 million at the end of 2024 [30][31] - Research and development expenses for 2025 were $12.7 million, with expectations for an increase in 2026 due to ongoing studies [28][29] Q&A Session Summary Question: Drivers of growth for 2026 guidance for Firdapse and AGAMREE - Management highlighted the significant pool of identified patients and increased RGCC testing as key growth drivers [36][37] Question: Factors behind the increase in Firdapse growth guidance - Management noted the efficiency in converting diagnosed patients to treatment and the increase in RGCC tests as major contributors [43][44] Question: Impact of SUMMIT study on AGAMREE forecast - Management indicated that while the SUMMIT study is important, current guidance does not factor in potential impacts from the study [66][69] Question: Changes in AGAMREE's median age of new enrollees - Management confirmed a decrease in median age, indicating younger patients are more likely to adhere to therapy [55][58] Question: Reimbursement landscape for AGAMREE - Management reported strong reimbursement rates above 85%, with some patients facing step edits [57][58] Question: Phase 1a readout impact on AGAMREE plans - Management stated that the readout will inform lifecycle management opportunities but does not currently impact guidance [88][90]

Financial Data and Key Metrics Changes - Total revenues for 2025 reached $589 million, a 19.8% increase from $491.7 million in 2024, exceeding previous guidance [21][23] - Net product revenue for 2025 was $588.8 million, reflecting a 20.3% increase over 2024 [4][23] - GAAP net income for 2025 was $214.3 million, or $1.68 per diluted share, a 30.8% increase compared to $163.9 million in 2024 [24][23] - Non-GAAP net income for 2025 was $346.2 million, or $2.72 per diluted share, compared to $276.3 million, or $2.21 per diluted share in 2024 [24][25] Business Line Data and Key Metrics Changes - Firdapse generated $358.4 million in revenue for 2025, a 17% increase year-over-year [5][19] - AGAMREE achieved $117.1 million in revenue for 2025, representing a 154.3% year-over-year growth [8][17] - Fycompa generated $113.3 million in revenue for 2025, despite facing generic competition [10][19] Market Data and Key Metrics Changes - The addressable market for LEMS is estimated to exceed $1 billion, with significant growth opportunities in both idiopathic and cancer-associated LEMS [6][16] - The company reported a 21% year-over-year increase in RGCC testing, which is critical for patient identification [38][44] Company Strategy and Development Direction - The company aims to maximize the potential of Firdapse and AGAMREE through targeted patient identification and market penetration strategies [32][11] - Business development efforts are focused on identifying differentiated rare disease products with a peak sales potential of up to $500 million [12][11] - The company plans to continue lifecycle management activities and explore additional indications for AGAMREE [91][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2026 revenue guidance of $615 million to $645 million, driven by continued growth in Firdapse and AGAMREE [4][22] - The company remains focused on maintaining operational excellence while capitalizing on market opportunities [3][20] Other Important Information - The company ended 2025 with cash and cash equivalents of $709.2 million, an increase from $517.6 million at the end of 2024 [30][31] - Research and development expenses for 2025 were $12.7 million, with expectations to increase in 2026 [28][27] Q&A Session Summary Question: Drivers of growth for 2026 guidance for Firdapse and AGAMREE - Management highlighted the significant opportunity in both idiopathic and cancer-associated LEMS, with a pool of over 600 identified patients in the diagnostic journey [36][38] Question: Factors behind the increase in Firdapse growth guidance - The increase is attributed to the larger pool of identified patients and a 21% growth in RGCC tests, which aids in patient identification [44][46] Question: Impact of SUMMIT study on AGAMREE forecast - Management indicated that while the SUMMIT study is important, no significant impact is built into the current guidance as the endpoints are not yet in the label [69][70] Question: Changes in AGAMREE's median age of new enrollees - The median age has dropped by one year, indicating younger patients are being treated, which may enhance long-term adherence and benefits [59][60] Question: Reimbursement landscape for AGAMREE - Reimbursement rates are above 85%, with some step edits in place, but management is optimistic about converting patients during the approval process [58][59]

Core Insights - Catalyst Pharmaceuticals achieved record revenues of $589 million in 2025, reflecting a 20.3% growth in net product revenue driven by enhanced patient identification and market penetration [4] - FIRDAPSE's growth was supported by a 40% increase in identified patient leads and a 12% reduction in early discontinuations due to a new pharmacy outreach program [4] - AGAMREE reached 100% penetration in top Centers of Excellence, capturing 80% of the Duchenne Muscular Dystrophy patient population [4] - The company plans to transition FYCOMPA to a non-promoted status following generic entry while still contributing to revenue [4] - Business development activity surged with over 100 assessments in 2025, with 90% being inbound inquiries [4] Strategic Performance and Operational Drivers - The company attributes its commercial success to a 'plug-and-play' infrastructure utilizing AI and machine learning to prioritize high-urgency patient leads [4] - Total revenue guidance for 2026 is set between $615 million and $645 million, assuming continued expansion in idiopathic and cancer-associated LEMS markets [4] - The strategy for FIRDAPSE in 2026 includes integrating updated NCCN guidelines into oncology care pathways to tap into the under-penetrated cancer-associated LEMS segment [4] - AGAMREE's growth is expected to deepen within existing Centers of Excellence, supported by a 5-year SUMMIT follow-up study [4] Financial Outlook - A $12.5 million milestone payment was triggered in Q4 2025 as AGAMREE's net product revenue surpassed the $100 million threshold [6] - R&D expenses are forecasted to rise to $17.5 million - $22.5 million in 2026 to support AGAMREE life cycle management and new indication assessments [6] - FYCOMPA revenue is expected to decline significantly, with 2026 guidance set at $40 million to $45 million following the cessation of active promotion [4] Legal Considerations - A patent infringement trial against Hetero USA is scheduled for March 23, 2026, to protect FIRDAPSE's intellectual property ahead of the 30-month stay expiration [4]

Core Insights - Analysts project Catalyst Pharmaceutical (CPRX) will report quarterly earnings of $0.42 per share, reflecting a 40% decline year over year [1] - Revenue estimates for the quarter are set at $140.02 million, indicating a 1.3% decrease from the same period last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, suggesting stability in analysts' forecasts [1] Revenue Projections - Analysts expect 'Revenues- Product revenue, Net- FIRDAPSE' to be $96.43 million, representing a year-over-year increase of 16.9% [4] - The consensus for 'Revenues- Product revenue, Net- FYCOMPA' is $12.28 million, indicating a significant decline of 67.9% year over year [4] - For 'Revenues- Product revenue, Net- AGAMREE', analysts project $31.30 million, reflecting a year-over-year increase of 48.5% [4] Overall Performance - The average prediction for 'Revenues- Product revenue, net' stands at $140.01 million, showing a year-over-year change of -1.3% [5] - Over the past month, Catalyst shares have gained 0.5%, while the Zacks S&P 500 composite has decreased by 1% [5] - Catalyst holds a Zacks Rank of 3 (Hold), suggesting its performance is expected to align with the overall market in the near term [5]

Core Thesis - Catalyst Pharmaceuticals, Inc. is positioned as a leading player in the rare-disease biopharma sector, focusing on two main products: FIRDAPSE and AGAMREE, which provide significant growth potential and market exclusivity [2][5]. Product Overview - FIRDAPSE (amifampridine) is the only FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) in patients aged six and older, with patent protection until February 2035, creating a near-monopoly [2]. - AGAMREE (vamorolone) is approved for Duchenne Muscular Dystrophy (DMD) in patients two years and older, designed to minimize long-term side effects while maintaining therapeutic benefits [3]. Financial Performance - For Q2 2025, Catalyst reported revenues of $146.6 million, reflecting a 19.4% year-over-year increase, with a net income of $52.1 million and a net margin exceeding 35% [4]. - The company has a strong cash position of $652.8 million and no debt, along with a $200 million share repurchase program, enhancing its financial flexibility [4]. Growth Strategy and Future Catalysts - The company is expanding its market reach by promoting a higher daily dose of FIRDAPSE and targeting cancer-associated LEMS patients [3]. - Upcoming catalysts include Q3 financial results, Canadian approval for AGAMREE, interim data from the SUMMIT study, and potential acquisitions, which could significantly enhance the company's valuation [5]. Market Position and Investment Potential - Despite facing generic competition with FYCOMPA, Catalyst's rare-disease portfolio offers durable exclusivity and high-margin growth opportunities [5]. - The combination of long-term product exclusivity, differentiated growth strategies, strong cash reserves, and strategic options positions Catalyst as a compelling investment opportunity in the rare-disease sector [5].

Company Overview - Catalyst Pharmaceuticals is a commercial stage biopharmaceutical company focused on rare diseases, aiming to in-license, purchase, and develop products for these conditions [4]. Product Portfolio - The company has two key molecules: FIRDAPSE, which is the only evidence-based product approved for Lambert-Eaton myasthenic syndrome (LEMS), and AGAMREE [5]. Industry Context - The presentation took place at the 44th Annual JPMorgan Healthcare Conference, highlighting the company's engagement with investors and the healthcare community interested in rare diseases [2][3].